Collaborators

In partnership with the world-renowned Gene Editing Institute team at ChristianaCare, Rockland has developed revolutionary CRISPR in a Box™ Educational Kits to introduce students across the world to invaluable genomic engineering techniques in efforts to train the next generation of scientists.   

We are pleased to support Lehigh University's SickleID project in developing low-cost sickle cell screening devices for low- to middle-income countries. Rockland's hemoglobin antibodies are critical components for SickleID lateral flow assays.

Rockland has partnered with Diagnostic Biosystems (DBS) to offer novel immunohistochemistry antibodies, supporting reagents, and cutting-edge equipment to diagnostic and IHC researchers for the advancement of research in anatomic pathology and histology areas of research.   

As part of Rockland's family of companies, we've joined with Abzyme Therapeutics to offer their patent-pending approach for the rapid optimization of pH-dependent antibodies for safer and more effective cancer biologics.

Rockland has partnered with The Wistar Research Institute, to produce, validate and distribute a diverse panel of patient-derived, low-passage melanoma cell lines from freshly excised metastases. These preclinical tumor cell line models can facilitate cancer research be by identifying critical target genes and pathways enacted by genomic alterations and enabling more accurate predictions of effectiveness for novel cancer therapeutics.

As part of Rockland's family of companies, we've joined with Abzyme Therapeutics to offer their patent-pending approach for the rapid optimization of pH-dependent antibodies for safer and more effective cancer biologics.

Rockland collaborates with LIMR to provide monoclonal and polyclonal antibodies, which bind biomarkers crucial for cell signaling, immune system regulation, inflammatory responses, cellular metabolism, and cancer progression.

Rockland has collaborated with Wheaton on the development of the CELLine Bioreactor Flask, which can help labs cut costs while providing high quality results in a number of analyses, including Western Blot, ELISA and immunohistochemistry assays.

Rockland Immunochemicals has collaborated with Bio-Rad to develop an enhanced multiplex fluorescent western blotting protocol. The assays produce high resolution immunoblots on PVDF membrane, providing increased visibility and profiling of low abundance proteins.

Rockland has collaborated with Leica Microsystems to jointly analyze the sub-cellular localization of Akt using high-resolution STED microscopy.

The partnership with St. Jude Children's Research Hospital was the first of Rockland's collaborations and was integral to our development of antibodies involved in signal transduction and cancer research. The partnership combined basic and translational research, working with life science researchers to develop enhanced bioreagents, e.g. our ATM phospho S1981 antibody, to ease biomedical research.

Rockland is a proud member and supporter of the Sino-American Pharmaceutical Professionals Association - Greater Philadelphia (SAPA-GP), one of the most active and reputable organizations that fosters the development of it's members and the general public with high-quality scientific programs and facilitates the advancement of pharmaceutical science and technology between the US and China.

Syngene is a supplier of gel documentation (gel doc) systems for rapid and accurate imaging and analysis of 1D gels, 2D gels, fluorescent, and chemiluminescent blots. Rockland has developed DyLight™ Multiplex Fluorescent Western Blotting Kits for use with Syngene's G:BOX Gel Imaging System or equivalent.

Precision Biosystem's BlotCycler combined with Rockland’s extensive range of DyLight fluorochrome conjugated secondary antibodies offer a time-saving alternative and an improved quality of results.

Pall Life Sciences, a global leader in life science products and services, has teamed up with Rockland Immunochemicals to demonstrate the impact of high quality products in Western blotting.